CA3096033A1 - Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells - Google Patents

Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells Download PDF

Info

Publication number
CA3096033A1
CA3096033A1 CA3096033A CA3096033A CA3096033A1 CA 3096033 A1 CA3096033 A1 CA 3096033A1 CA 3096033 A CA3096033 A CA 3096033A CA 3096033 A CA3096033 A CA 3096033A CA 3096033 A1 CA3096033 A1 CA 3096033A1
Authority
CA
Canada
Prior art keywords
hct
years
mscs
months
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3096033A
Other languages
English (en)
French (fr)
Inventor
Joanne Kurtzberg
Geraldine DAWSON
Jessica Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68101425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3096033(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duke University filed Critical Duke University
Publication of CA3096033A1 publication Critical patent/CA3096033A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Educational Technology (AREA)
  • Hospice & Palliative Care (AREA)
CA3096033A 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells Pending CA3096033A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652722P 2018-04-04 2018-04-04
US62/652,722 2018-04-04
PCT/US2019/025716 WO2019195506A1 (en) 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells

Publications (1)

Publication Number Publication Date
CA3096033A1 true CA3096033A1 (en) 2019-10-10

Family

ID=68101425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3096033A Pending CA3096033A1 (en) 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells

Country Status (12)

Country Link
US (1) US12491210B2 (https=)
EP (1) EP3773486B1 (https=)
JP (1) JP2021520380A (https=)
KR (1) KR20210031853A (https=)
CN (1) CN112351785A (https=)
AU (1) AU2019247210A1 (https=)
BR (1) BR112020020295A2 (https=)
CA (1) CA3096033A1 (https=)
ES (1) ES2968823T3 (https=)
IL (1) IL277733B2 (https=)
SG (1) SG11202009805PA (https=)
WO (1) WO2019195506A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057969A (zh) * 2021-03-09 2021-07-02 吴志新 一种间充质干细胞对儿童自闭症临床应用实验方法
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
US9347956B2 (en) 2010-12-16 2016-05-24 Autism Biotech Limited Biomarker and uses thereof in diagnosis, treatment of autism
AU2017235446A1 (en) 2016-03-16 2018-11-08 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy
US20170296588A1 (en) * 2016-04-19 2017-10-19 AngioStem, Inc. Mesenchymal stem cells derived from placental sources
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
US10987381B2 (en) 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis

Also Published As

Publication number Publication date
EP3773486A1 (en) 2021-02-17
BR112020020295A2 (pt) 2021-01-12
IL277733B1 (en) 2024-06-01
AU2019247210A1 (en) 2020-11-05
EP3773486B1 (en) 2023-12-06
IL277733A (en) 2020-11-30
US20210128631A1 (en) 2021-05-06
SG11202009805PA (en) 2020-11-27
IL277733B2 (en) 2024-10-01
US12491210B2 (en) 2025-12-09
KR20210031853A (ko) 2021-03-23
WO2019195506A1 (en) 2019-10-10
JP2021520380A (ja) 2021-08-19
ES2968823T3 (es) 2024-05-14
CN112351785A (zh) 2021-02-09
EP3773486A4 (en) 2021-12-15
EP3773486C0 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
Sun et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder
Dawson et al. Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial
Orobets et al. The advantage of exosomes as vectors of drugs
Schlosser-Brandenburg et al. Influence of nutrition and maternal bonding on postnatal lung development in the newborn pig
US12491210B2 (en) Methods of assessing and treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Sanyaolu et al. Current modalities of sickle cell disease management
US11813294B2 (en) Methods for the treatment of autism spectrum disorders
AU2019247383B2 (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
HK40045701A (en) Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Fuh et al. Measuring Alzheimer's disease progression with transition probabilities in the Taiwanese population
Gesundheit et al. Mesenchymal stromal cell treatment alleviates autism spectrum disorder symptoms: a case report
Skuljec et al. Glatiramer Acetate Modifies the Immune Profiles of Monocyte-Derived Dendritic Cells In Vitro Without Affecting Their Generation
Liang et al. Case report: Treatment of Wilson’s disease by human amniotic fluid administration
US20200016213A1 (en) Methods of Treating Cerebral Palsy Using High Dose Allogeneic Umbilical Cord Blood
Nath Neuroinfectious Diseases-Case Reports Collection 2021
Motiwala et al. Human Umbilical Cord Blood Infusions in the Management of Autism Spectrum Disorder
Babinski Allogeneic Mesenchymal Stromal Cell Infusions Are Safe and Effective in Children with Autism Spectrum
Gauthier Mesenchymal Stem Cell Transplantation: A Novel Approach to Treating Progressive Neurological Diseases
Jin Implications of Chronic Infection on Skeletal Muscle Immunity, Regeneration, and Function
US20210353682A1 (en) Pharmaceutical product for preventing or treating alzheimer's disease
HK40044465A (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
Kurtzberg et al. ord

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220913

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250604

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251003

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251204

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251204